XML 99 R90.htm IDEA: XBRL DOCUMENT v3.25.3
Other Operating Income And Expenses - Additional Information (Details) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating income [1] € 533 € 563 [2]
Other operating expense [1] 2,476 1,977 [2]
Regeneron | Other operating income (expense)    
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating income 70 96
Other related parties | Other operating income (expense)    
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating income 87 121
Gains on divestment of some mature products 344 319
Other related parties | Regeneron | Commercialization Related Expenses [Member]    
Disclosure Of Other Operating Income Expenses [Line Items]    
Other operating expense € 2,331 € 1,841
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.